Science Current Events | Science News | Brightsurf.com
 

Cell skeleton may hold key to overcoming drug resistance in cancer

October 04, 2007

Researchers have uncovered a new way in which a cell protein protects cancer cells from a wide range of chemotherapeutic drugs, identifying a possible target for improving treatment outcomes for patients.

A team of scientists at Children's Cancer Institute Australia for Medical Research (CCIA), led by Associate Professor Maria Kavallaris, discovered that the bIII-tubulin component of the cell's cytoskeleton could play an important role in resistance to a wide range of drugs used to treat lung, ovarian and breast cancers.

Advanced non-small cell lung carcinomas (NSCLC) account for more than 80 per cent of lung cancer cases. More than one million people are diagnosed with lung cancer every year, the most common cancer in the world and the leading cause of cancer deaths. Chemotherapy remains the most effective treatment option, involving a diverse range of drugs, often used in combination. However, the emergence of drug-resistant tumours in NSCLC means chemotherapy no longer holds the promise of a good outcome for many patients.

Increased expression of bIII-tubulin has been linked to drug resistance in NSCLC, ovarian and breast cancers. In the latest Cancer Research publication, Associate Professor Kavallaris and her team showed that blocking the expression of the bIII-tubulin gene in NSCLC cells led to an increase in their sensitivity to a range of chemotherapeutic drugs.

"Our results strongly suggest that the bIII-tubulin component is responsible for protecting NSCLC cells from the action of key chemotherapeutic drugs," said Associate Professor Kavallaris.

"This is the first scientific evidence for the broader implications of abnormal expression of this protein.

"We now have new insight into a mechanism of drug resistance in NSCLC which has not previously been reported. This has important implications for improving the targeting and treatment of a number of cancers which are resistant to current chemotherapeutic drugs," said Associate Professor Kavallaris.

Research Australia


Related Chemotherapeutic Drug Current Events and Chemotherapeutic Drug News Articles


Non-integrating viral vector delivers chemotherapy-sensitizing gene to pancreatic cancer cells
New Rochelle, NY, February 26, 2016--A novel HIV-based lentiviral vector can introduce a gene to pancreatic tumor cells that makes them more sensitive to the chemotherapeutic drug gemcitabine, without integrating into cellular DNA.

Scientists pioneer 3-D-printed drug delivering micro-needles
Researchers have developed a new technique to produce a 3D 'micro-printed' array of needles capable of drug delivery.

Innovative light therapy reaches deep tumors
Light long has been used to treat cancer. But phototherapy is only effective where light easily can reach, limiting its use to cancers of the skin and in areas accessible with an endoscope, such as the gastrointestinal tract.

CNIO associates rare gene variants with side effects from chemotherapy with paclitaxel
Paclitaxel is a chemotherapeutic drug that has been shown to be highly effective when treating solid tumours, such as breast, ovarian and lung tumours.

Major discovery on the mechanism of drug resistance in leukemia and other cancers
A mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse, has been identified by Kathy Borden of the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) and her collaborators.

Genetic aberration paves the way for new treatment of cancer disease
Researchers from Faculty of Health and Medical Sciences, University of Copenhagen, have characterized a genetic aberration on a group of colorectal cancer patients.

Nanotech system, cellular heating may improve treatment of ovarian cancer
The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State University report in a new study.

Celery, artichokes contain flavonoids that kill human pancreatic cancer cells
Celery, artichokes, and herbs, especially Mexican oregano, all contain apigenin and luteolin, flavonoids that kill human pancreatic cancer cells in the lab by inhibiting an important enzyme, according to two new University of Illinois studies.

More Effective Immunotherapy for Melanoma Hinges on Blocking Suppressive Factors, Moffitt Cancer Center Researchers Say
Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them.

CWRU School of Medicine researchers discover gene that permanently stops cancer cell proliferation
Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.
More Chemotherapeutic Drug Current Events and Chemotherapeutic Drug News Articles

Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy (Cancer Drug Discovery and Development)

Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy (Cancer Drug Discovery and Development)
by Benjamin Bonavida (Editor)


This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies.

Basic and Clinical Pharmacology 13 E

Basic and Clinical Pharmacology 13 E
by Bertram Katzung (Author), Anthony Trevor (Author)


Gain a full understanding of the basic science and clinical use of drugs with the most up-to-date and comprehensive pharmacology text in the health sciences400 ILLUSTRATIONS--MANY IN FULL COLORA Doody's Core Title for 2015!Coverage that spans every aspect of medical pharmacology: Encompasses every aspect of medical pharmacology including botanicals and over-the-counter drugs New chapter on pharmacogenomics with important examples Emphasis is placed on discussion of drug groups and prototypes Clinically relevant, the book includes sections that specifically address the clinical choice and use of drugs in patients and the monitoring of their effects Full-color presentation with more than 400 illustrations Case studies introduce clinical problems in most chapters Summary tables and diagrams...

Anti-apoptotic and Pro-inflammatory Signaling in Cancer Cells: Status and Modulation by Chemotherapeutic Drugs

Anti-apoptotic and Pro-inflammatory Signaling in Cancer Cells: Status and Modulation by Chemotherapeutic Drugs
by Dr. Gabriele Imre (Author)


The transcription factor nuclear factor kappa-B (NFkB) plays a pivotal role in the immune response but is also involved in cancer development and progression. In unstimulated cells NFkB is kept inactive in the cytoplasm by inhibitor of NFkB (IkB) proteins. Dysregulation of the pathway or activation of NFkB by chemotherapeutic agents may lead to cancer progression or drug resistance. The NFkB activation status was investigated in human lung cancer, pancreatic cancer, and hematopoietic cancer cell lines. Additionally, the potential of cytotoxic drugs in activating the NFkB signaling pathway was analyzed. Furthermore, the influence of histone deacetylase inhibitors (HDIs) on the NFkB pathway in human non-small cell lung cancer (NSCLC) cell lines was investigated. Incubation of NSCLC cells...

Advances in DNA Repair in Cancer Therapy (Cancer Drug Discovery and Development)

Advances in DNA Repair in Cancer Therapy (Cancer Drug Discovery and Development)
by Lawrence Panasci (Editor), Raquel Aloyz (Editor), Moulay Alaoui-Jamali (Editor)


​A comprehensive review of the recent developments in DNA repair research that have potential for translational applications. The book explains in detail the various biological mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK. The book captures-for both cancer researchers and oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.​

Cancer Chemotherapeutic Agents (ACS Professional Reference Book)

Cancer Chemotherapeutic Agents (ACS Professional Reference Book)
by William O. Foye (Editor)


An authoritative treatment of the discovery, development, and understanding of cancer chemotherapeutic agents. Addresses the major classes of chemotherapeutic agents, including antimetabolites, agents that react with DNA, inhibitors of transcription enzymes, topoisomerase inhibitors, DNA minor-groove binding compounds, antimotic agents, bleomycin group antitumor antibiotics, antihormones, paclitaxels, and photochemically activated agents. Provides an overview of the various classes of agents now considered important. Examines a method for determining the similarity of mechanism of the compounds in a given class.

Basic and Clinical Pharmacology 12/E (LANGE Basic Science)

Basic and Clinical Pharmacology 12/E (LANGE Basic Science)
by Bertram G. Katzung (Author), Susan B. Masters (Author), Anthony J. Trevor (Author)


The most up-to-date, comprehensive, and authoritative pharmacology text in health medicine Enhanced by more than three hundred illustrations -- many in full color Organized to reflect the syllabi in many pharmacology courses and in integrated curricula, Basic & Clinical Pharmacology, 12e covers the important concepts students need to know about the science of pharmacology and its application to clinical practice. Selection of the subject matter and order of its presentation are based on the authors’ many years experience in teaching this material to thousands of medical, pharmacy, dental, podiatry, nursing, and other health science students. To be as clinically relevant as possible, the book includes sections that specifically address the clinical choice and use of drugs in...

Electroanalysis of Chemotherapeutic Drugs: Electrochemical analysis of drugs

Electroanalysis of Chemotherapeutic Drugs: Electrochemical analysis of drugs
by Nageswara Reddy Chennupalli (Author), Reddy Prasad Puthalapattu (Author), Bobby Naidoo Eliazer (Author)


This book discusses various electrochemical methods and their validation in chemotherapeutic drugs analysis and their progress and great impact on analytical chemistry. A great number of studies on chemotherapeutic drugs such as zolinza, zanosar and zinecard by various electroanalytical techniques. Electrochemical analysis often offers advantages over other analytical methods, such as a high degree of accuracy, precision, selectivity and also low cost of operation. It also focuses on collection of samples, experimental procedures and environmental and health issues concerning chemical technology are also addressed. The book consists of four chapters discussing various topics with updated references. The author is a highly qualified electroanalytical chemist with an impressive record of...

Glioblastoma Treatment with 2,5-Dimethyl-Celecoxib (DMC) In Vitro: Effects of Additional Chemotherapeutic Drugs and Tumor Microenvironment - ... Used In Vitro Cell Growth and Survival Assays

Glioblastoma Treatment with 2,5-Dimethyl-Celecoxib (DMC) In Vitro: Effects of Additional Chemotherapeutic Drugs and Tumor Microenvironment - ... Used In Vitro Cell Growth and Survival Assays
by Nathaniel Soriano (Author)


2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex®) that lacks COX-2 inhibitory function yet maintains all of celecoxibs anti-tumor properties. We set out to investigate the potential of combining current glioblastoma chemotherapies with DMC as a new approach to enhance glioblastoma cell killing. DMC was not only able to enhance tumor cell killing when combined with other drugs but also induced glioblastoma growth arrest and apoptosis in low glucose and hypoxic conditions which are normally associated with chemoresistance. Therefore, if DMC were used in combination it may potentially be able to reverse this chemoresistance and restore or even enhance these drugs inhibitory effects. In addition, we also...

Transition Metal Complexes as Drugs and Chemotherapeutic Agents (Catalysis by Metal Complexes)

Transition Metal Complexes as Drugs and Chemotherapeutic Agents (Catalysis by Metal Complexes)
by N. Farrell (Author)


When this book was first conceived as a project the expanding interest in the clinical use of platinum and gold complexes made a survey of the relevant biological properties of metal complexes timely and appropriate. This timeliness has not diminished during the gestation and final publica­ tion of the manuscript. The introduction contains an explanation of the layout and approach to the book, which I wrote as an overall survey of the wide variety of biological properties of metal complexes. Hopefully, the reader will see the parallels in mechanisms and behavior, even in different organisms. The writing was considerably helped by the enthusiasm and confidence (totally unearned on my part) in the project of Professor Brian James and lowe him my special thanks. I also owe a great debt of...

Burger's Medicinal Chemistry and Drug Discovery, Chemotherapeutic Agents (Burger's Medicinal Chemistry & Drug Discovery) (Volume 5)

Burger's Medicinal Chemistry and Drug Discovery, Chemotherapeutic Agents (Burger's Medicinal Chemistry & Drug Discovery) (Volume 5)
by Donald J. Abraham (Editor)


This is Volume 5: Chemotherapeutic Agents, of Burger's Medicinal Chemistry and Drug Discovery, 6th Edition. This new volume contains critical new chapters on Molecular Biology of Cancer, Synthetic Anti-angiogenic Agents and Selective Toxicities.

To purchase the entire 6 volume set, please refer to ISBN 0-471-37032-0.

For a complete list of articles and contributors as well as FREE sample chapters from this new 6th Edition please visit: www.mrw.interscience.wiley.com/bmcdd

© 2016 BrightSurf.com